The reliability of endoscopic biopsies in assessing HER2 status in gastric and gastroesophageal junction cancer: A study comparing biopsies with surgical samples

Translational Oncology

Volumn 6, Issue 1, 2013, Pages 10-16

  Grillo, Federica ^a   Fassan, Matteo ^b   Ceccaroli, Chiara ^a   Giacometti, Cinzia ^b   Curto, Monica ^a   Zagonel, Vittorina ^c   Ceppa, Paola ^a   Nitti, Donato ^b   Castoro, Carlo ^c   Fiocca, Roberto ^a   Rugge, Massimo ^b,c   Mastracci, Luca ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; DIAGNOSTIC ACCURACY; ENDOSCOPIC BIOPSY; ESOPHAGUS CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROESOPHAGEAL JUNCTION CANCER; GENE DOSAGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALUE; PROTEIN EXPRESSION; SCORING SYSTEM; STOMACH CANCER;

EID: 84874717686     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12334     Document Type: Article

References (36)

1. Kamangar F, Dores GM, and Anderson WF (2006). Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24, 2137-2150.
2. Ohtsu A (2008). Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol 43, 256-264.
3. Enzinger PC and Mayer RJ (2003). Esophageal cancer. N Engl J Med 349, 2241-2252.
4. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, and Hamilton SM (2005). Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 241, 27-39.
5. Fassan M, Mastracci L, Grillo F, Zagonel V, Bruno S, Battaglia G, Pitto F, Nitti D, Celiento T, Zaninotto G, et al. (2012). Early HER2 dysregulation in gastric and esophageal carcinogenesis. Histopathology 61, 769-776.
6. Normanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, De Luca A, Caponigro F, and Salomon DS (2005). The ErbB receptors and their ligands in cancer: an overview. Current Drug Targets 6, 243-257.
7. Ross JS and Fletcher JA (1999). HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 112, S53-S67.
8. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344, 783-792.
9. Fukushige S, Matsubara K, Yoshida M, Sasaki M, Suzuki T, Semba K, Toyoshima K, and Tamamoto T (1986). Localization of a novel v-erbB-related gene, c-erb B-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 6, 955-958.
10. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, and Nakano H (1999). The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85, 1894-1902.
11. Joergensen JT and Hersom M (2012). HER2 as a prognostic marker in gastric cancer-a systematic analysis of data from the literature. J Cancer 3, 137-144.
12. Joergensen JT (2010). Targeted HER2 treatment in advanced gastric cancer. Oncology 78, 26-33.
13. Reichelt U, Duesedau P, Tsourlakis MCH, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, et al. (2007). Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 20, 120-129.
14. Langer R, Von Rahden BH, Nahrig J, Von Weyhern C, Reiter R, Feith M, Stein HJ, Siewert JR, Höfler H, and Sarbia M (2006). Prognostic significance of expression patterns of c-erb B-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol 59, 631-634.
15. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687-697.
16. EMEA (2009). European Medicines Agency Opinion. Available at: www.emea. europa.eu/pdfs/human/opinion/Herceptin_82246709en.pdf.
17. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25, 118-145.
18. Sui W, Ou M, Chen J, Wan Y, Peng H, Qi M, Huang H, and Dai Y (2009). Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for HER-2 status in breast cancer. World J Surg Oncol 7, 83.
19. Yang J, Luo H, Li Y, Li J, Cai Z, Su X, Dai D, Du W, Chen T, and Chen M (2012). Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys 62, 221-228.
20. Hoffman M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, and Henkel T (2008). Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52, 797-805.
21. Gravalos C and Jimeno A (2008). HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19, 1523-1529.
22. Yan B, Yau EX, Bte Omar SS, Ong CW, Pang B, Yeoh KG, and Salto-Tellez M (2010). A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 63, 839-842.
23. Lee S, de Boer WB, Fermoyle S, Platten M, and Kumarasinghe MP (2011). Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology 59, 832-840.
24. Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, and Ochiai A (2006). Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15, 65-71.
25. Bosman F, Carniero F, Hruban R, and Thiese N (2010). WHO Classification of Tumours of the Digestive System. IARC Lyon Press, Lyon, France.
26. Laurén P (1965). The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64, 31-49.
27. Ming SC (1977). Gastric carcinoma. A pathobiological classification. Cancer 39, 2475-2485.
28. Sobin L, Gospodarowicz M, and Wittekind C (2009). TNM Classification of Malignant Tumours. (7th ed.). Blackwell Publishing Ltd, Oxford, UK.
29. Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, et al. (2010). HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457, 299-307.
30. Boers JE, Meeuwissen H, and Methorst N (2011). HER2 status in gastrooesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology 58, 383-394.
31. Bang YH, Chung H, Xu J, Lordick F, Sawaki A, Al-Sakaff N, Lipatov O, See C, Ruschoff J, and Van Cutsem E (2009). Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening program of the ToGA trial. J Clin Oncol 27, 15s.
32. Ridolfi RL, Jamehdor MR, and Arber JM (2000). HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 13, 866-873.
33. Grabsch H, Sivakumar S, Gray S, Gabbert HE, and Müller W (2010). HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell Oncol 32, 57-65.
34. Kim MA, Lee HJ, Yang HK, Bang YJ, and Kim WH (2011). Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 59, 822-831.
35. Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, Jang SJ, and Park YS (2011). Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 18, 2833-2840.
36. Cho EY, Srivastava A, Park K, Kim J, Lee MH, Do I, Lee J, Kim KM, Sohn TS, Kang WK, et al. (2012). Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas. Pathology 44, 216-220.